Test Price
2,800 AED✅ Home Collection Available
DYNC1H1 Gene (Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1, Autosomal Dominant) Genetic Test in UAE
Executive Summary & Core Metrics
Executive Summary
High-precision genetic test for detecting pathogenic variants causing autosomal dominant spinal muscular atrophy with lower extremity predominance (SMALED1). Results are 99.9% accurate via ISO 9001:2015 accredited laboratory. Price includes pre‑test genetic counseling and premium home sample collection.
Legal & Regulatory Compliance
This test adheres to the UAE’s Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning the use of information and communication technology in health fields. Patient consent is governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. No test is performed without prior informed consent.
Test Overview & Methodology
The DYNC1H1 gene test detects pathogenic variants linked to autosomal dominant spinal muscular atrophy with lower extremity predominance (SMALED1), an adult‑onset neuromuscular disorder. Next‑generation sequencing (NGS) is used to analyse the full coding region and splice sites, providing molecular certainty for diagnosis and family planning.
| Feature | DNA Labs UAE | Closest Alternative |
|---|---|---|
| Precision | NGS with 150× mean coverage; full coding region + splice sites | Sanger sequencing of selected exons (limited) |
| Method | ISO 9001:2015 certified lab, DHA-licensed (License 1143) | Overseas lab without local UAE compliance |
| Speed | 3–4 weeks with dedicated pre‑ and post‑test genetic counseling | 4–8 weeks, no integrated clinical support |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I understand the anxiety a progressive muscle weakness diagnosis can bring. The DYNC1H1 NGS test provides molecular certainty essential for family planning and targeted physiatry interventions, but always interpret results alongside a thorough neurological examination and electromyography. Do not discontinue any prescribed medication based solely on genetic test outcomes without a face‑to‑face consultation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Clinical Advisory
Clinical notice: Do not discontinue prescribed medication or alter treatment plans without consulting your treating physician. Genetic results inform long‑term care but do not replace acute medical advice.
Patient Safety – Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Inability to provide informed consent (legal guardian required per UAE PDPL for minors)
- Active systemic infection or unstable medical condition precluding safe blood draw
- Severe bleeding disorder without prior coagulation workup
ER Red Flags – Seek Immediate Medical Attention
- Rapidly progressive limb weakness developing over hours or days
- Respiratory distress or difficulty swallowing (bulbar involvement)
- Sudden loss of ambulation or frequent falls
Patient FAQ & Clinical Guidance
1. What is the DYNC1H1 gene test, and who should consider it?
Direct Answer: It identifies pathogenic variants in the DYNC1H1 gene causing adult‑onset lower‑extremity‑predominant spinal muscular atrophy; indicated for progressive leg weakness and a positive family history.
2. How is the test performed and what sample is required?
Direct Answer: A simple blood draw (peripheral whole blood) via VIP mobile phlebotomy; no fasting required. Pre‑test genetic counseling is mandatory for informed consent.
3. What is the turnaround time and total cost in the UAE?
Direct Answer: Results are delivered in 3–4 weeks for AED 2,800, inclusive of pre‑test genetic counseling, home sample collection, and telephonic post‑test guidance.
UAE Regulatory & Data Privacy Adherence
This genetic test complies fully with the UAE’s data protection framework: Federal Decree‑Law No. 45 of 2021 (PDPL) governs the processing of personal data, and Federal Law No. 2 of 2019 regulates the use of information technology in healthcare. All patient information is encrypted, stored securely, and never shared without explicit consent. For clinical safety, Federal Decree‑Law No. 4 of 2016 on Medical Liability provides the legal basis for patient consent and medical oversight.
Clinical & Logistical Metadata
| Test Name | DYNC1H1 Gene (Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1, Autosomal Dominant) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks (21–28 days) |
| Sample Type / Matrix | Peripheral whole blood; VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection |
| Methodology Used | Next‑Generation Sequencing (NGS) – full coding region + splice sites |
| ICD‑10‑CM Code | G12.1 |
| LOINC Code | 23866-1 |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians